



February 9, 2017

TG Therapeutics, Inc. to Present at the 2017 BIO CEO & Investor Conference

Presentation Scheduled for Monday, February 13, 2017 at 9:00am ET

NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the 2017 BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City. The presentation is scheduled to take place on Monday, February 13, 2017 at 9:00am ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublrituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 recently entering clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

TGTX - G

CONTACT:

Jenna Bosco

Vice President- Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: ir@tgtxinc.com

 Primary Logo

Source: TG Therapeutics, Inc.

News Provided by Acquire Media